Linked Life Data

21692698

Source:http://linkedlifedata.com/resource/pubmed/id/21692698

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2011-6-22
pubmed:abstractText
Advances in the molecular characterization of human tumors have led to increased interest in the development of targeted therapeutics to include cancer vaccines. The recent success of sipuleucel-T, an autologous cellular vaccine administered to patients with hormone-refractory metastatic prostate cancer, suggests that this is a viable therapeutic option in the management of patients with solid tumors. This article focuses on breast cancer vaccines emphasizing delivery platforms, target antigens and novel strategies designed to enhance response to vaccination that are being evaluated in ongoing Phase II clinical trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1744-8395
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
755-74
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.
pubmed:affiliation
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
pubmed:publicationType
Journal Article, Review